Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MBRX 
Moleculin Biotech Inc (MBRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: MBRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7
1 Year Target Price $7
| 0 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.46% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.41M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 3 | Beta 1.56 | 52 Weeks Range 0.25 - 4.71 | Updated Date 06/30/2025 |
52 Weeks Range 0.25 - 4.71 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.99 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -62.45% | Return on Equity (TTM) -214.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2827848 | Price to Sales(TTM) - |
Enterprise Value -2827848 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.52 | Shares Outstanding 14127500 | Shares Floating 11828103 |
Shares Outstanding 14127500 | Shares Floating 11828103 | ||
Percent Insiders 4.42 | Percent Institutions 6.13 |
Analyst Ratings
Rating 2 | Target Price 7 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Moleculin Biotech Inc
Company Overview
History and Background
Moleculin Biotech Inc. was founded in 2003. It focuses on the development of therapies for hard-to-treat tumors and viruses. Its history includes preclinical and clinical development of various drug candidates.
Core Business Areas
- Drug Development: Focuses on developing and commercializing cancer and viral disease therapies.
- Preclinical and Clinical Programs: Involves research and development activities leading to potential drug approvals.
Leadership and Structure
The leadership team includes a CEO, CFO, and Chief Medical Officer. The organizational structure comprises departments focused on research, clinical development, and operations.
Top Products and Market Share
Key Offerings
- Annamycin: A next-generation anthracycline designed to avoid multidrug resistance mechanisms, in clinical trials for soft tissue sarcoma and AML. Market share data not publicly available. Competitors include established anthracycline drugs like doxorubicin.
- WP1066: An STAT3 inhibitor being studied for its potential in treating glioblastoma and other cancers. Market share data not publicly available. Competitors include other STAT3 inhibitors in development.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk, high reward drug development. It is driven by innovation, regulatory approvals, and market demand for new therapies.
Positioning
Moleculin Biotech Inc. is a small-cap biotech company focused on developing novel therapies for unmet medical needs. Its competitive advantage lies in its potentially differentiated drug candidates.
Total Addressable Market (TAM)
The TAM for cancer therapies is estimated in the hundreds of billions of dollars. Moleculin is positioned to capture a fraction of this market with successful drug development.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Small market capitalization
Opportunities
- Positive clinical trial results
- Strategic partnerships
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
Competitive Landscape
Moleculin Biotech Inc. faces intense competition from larger pharmaceutical companies with greater resources. Its success depends on demonstrating clinical efficacy and securing regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by fluctuations based on clinical trial results and funding rounds.
Future Projections: Future projections depend on the success of ongoing clinical trials and potential regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing Annamycin and WP1066 through clinical trials.
Summary
Moleculin Biotech Inc. is a high-risk, high-reward biotech company focused on novel cancer therapies. Its strengths lie in its innovative drug candidates, but it faces challenges due to limited resources and competition. The company's future hinges on successful clinical trial outcomes and strategic partnerships, requiring careful monitoring of its financial stability and regulatory landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough due diligence and consultation with a qualified financial advisor. Market share data are estimates and may not reflect the actual market share.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Moleculin Biotech Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2016-06-02 | Co-Founder, Chairman, President & CEO Mr. Walter V. Klemp | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://moleculin.com |
Full time employees 17 | Website https://moleculin.com | ||
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.